Final approval for generic version of Firazyr

Cipla Limited has received final approval for its Abbreviated New Drug Application (ANDA) for Icatibant Injectable 30mg/3mL from the United States Food and Drug Administration (US FDA).

Cipla’s Icatibant Injectable Pre-Filled Syringe 30mg/3mL is AP-rated generic version of Shire’s Firazyr. Icatibant injection is indicated for the treatment of acute attacks of HAE in adults 18 years of age and older.
(Source: Cipla)

2020-07-15T08:32:02+02:00July 15, 2020|HAEi News|